BRAF and chronic myelomonocytic leukemia: Zhang et al. indicated that a subset of patients with RAS wild-type chronic myelomonocytic leukemia (CMML) harbors BRAF kinase domain mutations that are potentially capable of activating the MAPK signaling pathway [10].